Dual inhibition: Combining epidermal growth factor-targeted therapies in non-small-cell lung cancer

Cheryl Ho, Angela Davies, Philip Mack, David R Gandara

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The epidermal growth factor receptor (EGFR) pathway is an important target in the treatment of advanced non-small-cell lung cancer. Therapeutic modulation of this pathway has focused on inhibiting the EGFR tyrosine kinase or competitively binding the receptor. Each method of EGFR inhibition is imperfect, with alternate cellular mechanisms variably enabling continued proliferation and malignant growth. In addition, de novo or acquired resistance is common with either one of these approaches. The use of both strategies simultaneously to block the EGFR signaling cascade, so-called dual inhibition, might theoretically overcome these limitations and improve efficacy. Preclinical data support this concept, and clinical trials are under way to investigate the safety and efficacy of combined EGFR inhibition.

Original languageEnglish (US)
Pages (from-to)420-424
Number of pages5
JournalClinical Lung Cancer
Volume8
Issue number7
DOIs
StatePublished - Jul 2007

Keywords

  • Monoclonal antibodies
  • Stable disease
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Dual inhibition: Combining epidermal growth factor-targeted therapies in non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this